InVitae Corp (N:NVTA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 1400 16th St
Tel: N/A
IR: See website
Key People
Sean E. George
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Shelly D. Guyer
Chief Financial Officer
Lee Bendekgey
Chief Operating Officer, Secretary
Patricia E. Dumond
Principal Accounting Officer
Thomas R. Brida
General Counsel
Robert L. Nussbaum
Chief Medical Officer
Katherine A. Stueland
Chief Commercial Officer
Business Overview
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
Financial Overview
For the nine months ended 30 September 2019, InVitae Corp revenues increased 47% to $150.5M. Net loss increased 66% to $165.1M. Revenues reflect United States segment increase of 47% to $140.7M, Rest of World segment increase of 97% to $6.8M. Higher net loss reflects Selling and Marketing - Balancing value increase of 59% to $81.8M (expense), Stock-based Compensation in R&D increase from $5.2M to $30.8M (expense).
Employees: 1,100 as of Sep 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,672M as of Sep 30, 2019
Annual revenue (TTM): $195.90M as of Sep 30, 2019
EBITDA (TTM): -$176.57M as of Sep 30, 2019
Net annual income (TTM): -$194.90M as of Sep 30, 2019
Free cash flow (TTM): -$128.50M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 96,522,073 as of Nov 1, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization